London, 01 September 2015 – Technavio has published a new report on the global duchenne muscular dystrophy drugs market, which is expected to grow at a CAGR exceeding 152% from 2015-2019.
About the Report
The latest report by Technavio draws attention towards the entry of novel drug candidates such as Marathon Pharmaceuticals’ MP-104, drisapersen by BioMarin Pharmaceutica, ataluren (Translarna) by PTC Therapeutics, and Sarepta Therapeutics’ eteplirsen and Santhera Pharmaceuticals’ Raxone.
“The arrival of novel drug candidates in the market is expected to propel market growth by generating a substantial amount of revenue. These drugs are also expected to cater to the substantial unmet medical needs in the market,” says Faisal Ghaus, Vice President of Technavio.
The latest report by Technavio also focuses on the strategic alliances vendors are forming to increase their market shares.
“Co-development agreements, if translated into commercial agreements, prove highly beneficial as the distribution channels of both development partners can be used to commercialize a drug,” adds Ghaus.
Market Scope and Calculation of Market Size
The new Technavio report covers the present scenario and growth prospects of the global Duchenne muscular dystrophy drugs market from 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of Duchenne muscular dystrophy.
Key Information Covered in the Report:
Key Vendors:
- BioMarin Pharmaceutical
- Lilly
- PTC Therapeutics
- Sarepta Therapeutics
- Santhera Pharmaceuticals
Market Growth Drivers:
- High unmet medical needs
- For a full detailed list, view our report.
Market Challenges:
- High cost of therapy
- For a full detailed list, view our report.
Market Trends:
- Focus on novel targets
- For a full detailed list, view our report.
https://www.technavio.com/%3Cp%3E%3Cstrong%3E%3Ca%20href%3D%22http%3A//ww…
